Overview

STAAR-3 Clinical Study

Status:
Completed

Trial end date:
2004-05-01

Target enrollment:

Participant gender:

Summary

To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa